Related references
Note: Only part of the references are listed.Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
Shengxiang Ren et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
Tao Jiang et al.
MOLECULAR CANCER (2022)
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Anne-Laure Desage et al.
FRONTIERS IN ONCOLOGY (2022)
Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC
Vichitra Behel et al.
CLINICAL LUNG CANCER (2022)
Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis
Yutian Zou et al.
EBIOMEDICINE (2021)
Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
Xi Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Filippo G. Dall'Olio et al.
CLINICAL LUNG CANCER (2021)
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer
Alvise Berti et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
98O First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA
L. Paz-Ares et al.
Journal of Thoracic Oncology (2021)
Liquid Biopsy: From Discovery to Clinical Application
Catherine Alix-Panabieres et al.
CANCER DISCOVERY (2021)
Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
Qiao Yang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
Biagio Ricciuti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Mio Ikeda et al.
CANCERS (2021)
Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Yuhui Ma et al.
FRONTIERS IN ONCOLOGY (2021)
Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
Xiaohong Wang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer
Lea Sinoquet et al.
CLINICAL CHEMISTRY (2021)
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
Paul van der Leest et al.
MOLECULAR ONCOLOGY (2021)
Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab
Patricia Mondelo-Macia et al.
MOLECULAR ONCOLOGY (2021)
Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis
Yushu Ouyang et al.
CANCER MEDICINE (2021)
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy
Wei Zou et al.
JCO PRECISION ONCOLOGY (2021)
Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer
Cheol-Kyu Park et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
The Different Facets of Liquid Biopsy: A Kaleidoscopic View
Zahra Eslami-S et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2020)
TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer
Jiefei Han et al.
CANCER IMMUNOLOGY RESEARCH (2020)
PD-L1+ aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients
Lina Zhang et al.
CANCER LETTERS (2020)
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal et al.
CLINICAL CANCER RESEARCH (2020)
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
Matthew D. Hellmann et al.
CLINICAL CANCER RESEARCH (2020)
Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors
Zhijie Wang et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors
Angelo Castello et al.
CANCERS (2020)
Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.
Marina Chiara Garassino et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
Perspective: The future of liquid biopsy
Catherine Alix-Panabieres
NATURE (2020)
Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer
William Jacot et al.
CLINICAL CHEMISTRY (2020)
Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
Maria A. Papadaki et al.
CANCERS (2020)
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
D. Marinelli et al.
ANNALS OF ONCOLOGY (2020)
Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)
J. Wang et al.
ANNALS OF ONCOLOGY (2020)
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Barzin Y. Nabet et al.
CELL (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
Yao Chen et al.
FRONTIERS IN ONCOLOGY (2020)
International liquid biopsy standardization alliance white paper
Dana Connors et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer
Young Kwang Chae et al.
ONCOLOGIST (2019)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
Menno Tamminga et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
Angela Alama et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Melanie Janning et al.
CANCERS (2019)
EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer
C. R. Lindsay et al.
EUROPEAN JOURNAL OF CANCER (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
LBA83Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
M Socinski et al.
ANNALS OF ONCOLOGY (2019)
LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
L Paz-Ares et al.
ANNALS OF ONCOLOGY (2019)
Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy
Li Li et al.
CANCER MEDICINE (2019)
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Valsamo Anagnostou et al.
CANCER RESEARCH (2019)
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Sarah B. Goldberg et al.
CLINICAL CANCER RESEARCH (2018)
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
Nicolas Guibert et al.
LUNG CANCER (2018)
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer
Manjima Dhar et al.
SCIENTIFIC REPORTS (2018)
Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
Etienne Giroux Leprieur et al.
ONCOIMMUNOLOGY (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
Application of Cell-free DNA Analysis to Cancer Treatment
Ryan B. Corcoran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab
Rajiv Raja et al.
CLINICAL CANCER RESEARCH (2018)
Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer
Yuki Iijima et al.
EUROPEAN JOURNAL OF CANCER (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study
L. Cabel et al.
ANNALS OF ONCOLOGY (2017)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
Chiara Nicolazzo et al.
SCIENTIFIC REPORTS (2016)
Frequent expression of PD-L1 on circulating breast cancer cells
Martine Mazel et al.
MOLECULAR ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2014)
Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System
Masahito Hosokawa et al.
PLOS ONE (2013)
Share Paper
